MRKR - Marker Therapeutics GAAP EPS of -$0.47 revenue of $0.76M August, 14 2023 05:41 PM Marker Therapeutics Inc. 2023-08-14 17:41:57 ET Marker Therapeutics press release ( NASDAQ: MRKR ): Q2 GAAP EPS of -$0.47. Revenue of $0.76M (-3.8% Y/Y). Shares +3.43% AH. For further details see: Marker Therapeutics GAAP EPS of -$0.47, revenue of $0.76M